NDC product
Emerphed
NDC 14789-250 · Nexus Pharamaceuticals Inc.
Key facts
| Product NDC | 14789-250 |
|---|---|
| Proprietary name | Emerphed |
| Nonproprietary name | Ephedrine Sulfate |
| Substances | EPHEDRINE SULFATE |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | Nexus Pharamaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA213407 |
| Pharmacologic classes | Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Increased Norepinephrine Activity [PE], Norepinephrine Releasing Agent [EPC], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC] |
| Marketing start | May 15, 2020 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: